EMPACT-MI

This clinical trial is enrolling participants that have had a heart attack, (also called acute myocardial infarction or MI). Even though treatments have made progress, researchers are still trying to improve care for heart attack patients, who are at increased risk for heart failure and death. The purpose of this trial is to find out if a drug called empagliflozin, in addition to normal care, will reduce the risk of heart failure and death in patients who are hospitalised for acute MI. The drug called empagliflozin has not been approved by the U.S. Food and Drug Administration (FDA) for your specific condition but it has been approved by the FDA for other uses. It has been approved by the FDA (brand name Jardiance®) to treat type 2 diabetes and to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease. Other drugs from the same medication class have been approved by the FDA for similar and other conditions. All conditions for which empagliflozin or drugs from the same class have been approved by the FDA are listed in the table below.